Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Arrivent Biopharma Inc (AVBP)

Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer GlobeNewswire - Mon Dec 22, 7:00AM CST

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to support...

AVBP : 22.29 (-0.13%)
ArriVent BioPharma Reports Third Quarter 2025 Financial Results GlobeNewswire - Mon Nov 10, 7:00AM CST

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17...

AVBP : 22.29 (-0.13%)
ArriVent Appoints Brent S. Rice as Chief Commercial Officer GlobeNewswire - Mon Sep 22, 3:05PM CDT

NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...

AVBP : 22.29 (-0.13%)
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer GlobeNewswire - Tue Sep 9, 7:00AM CDT

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Confirmed overall response rate (cORR) 68.2% and duration...

AVBP : 22.29 (-0.13%)
ArriVent BioPharma Reports Second Quarter 2025 Financial Results GlobeNewswire - Mon Aug 11, 7:00AM CDT

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient...

AVBP : 22.29 (-0.13%)
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 GlobeNewswire - Mon Jul 21, 7:00AM CDT

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent...

AVBP : 22.29 (-0.13%)
New Strong Sell Stocks for July 21st
New Strong Sell Stocks for July 21st Zacks Investment Research - Mon Jul 21, 6:18AM CDT

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Cadiz CDZI acquires and develops water-related land and agricultural assets. The Zacks Consensus Estimate for its current year...

ACCO : 3.69 (+0.54%)
AVBP : 22.29 (-0.13%)
CDZI : 5.71 (-0.52%)
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Jul 1, 10:15PM CDT

AVBP : 22.29 (-0.13%)
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Jul 1, 3:05PM CDT

AVBP : 22.29 (-0.13%)
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study GlobeNewswire - Mon Jun 23, 6:00AM CDT

AVBP : 22.29 (-0.13%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - Thu Dec 25, 6:30PM CST
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot